Please login to the form below

Not currently logged in
Email:
Password:

alteplase

This page shows the latest alteplase news and features for those working in and with pharma, biotech and healthcare.

Biogen hands out $120m upfront for Remedy stroke drug

Biogen hands out $120m upfront for Remedy stroke drug

The US biotech major is paying $120m upfront for rights to the drug, which is vying to be the first new treatment for ischaemic stroke since alteplase - still the only approved

Latest news

  • AZ's Brilinta disappoints in stroke trial AZ's Brilinta disappoints in stroke trial

    Currently the only drug approved for the treatment of ischemic stroke is Genentech's tissue plasminogen activator (tPA) Activase (alteplase), although this remains a controversial therapy as the drug has an

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

  • Lundbeck's desmoteplase flunks phase III stroke trial Lundbeck's desmoteplase flunks phase III stroke trial

    An older thrombolytic called alteplase (tPA) - sold by Genentech as Activase - is already approved to treat stroke, but remains a controversial therapy as the drug has an extremely narrow therapeutic window ... The drug is also easier to administer than

  • NICE stroke guidance boost for Boehringer's Actilyse NICE stroke guidance boost for Boehringer's Actilyse

    NICE stroke guidance boost for Boehringer's Actilyse. Institute changes guidance on alteplase use. ... Until now Actilyse (alteplase) was indicated for use in patients between three and 4.5 hours of the onset of symptoms, but the new NICE final guidance

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics